Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints new board members

Brussels-based biopharmaceutical company, UCB, has announced Bert De Graeve and Alexandre Van Damme as candidates for the Board

Brussels-based biopharmaceutical company, UCB, has announced Bert De Graeve and Alexandre Van Damme as candidates to join the Board at the company's general assembly on April 29.  After three terms on the Board, Prince Lorenz will step down at the forthcoming assembly. UCB's Board of Directors and Executive Committee thanked him for his contributions.

Bert De Graeve is chief executive officer of the Bekaert Group. He is also a member of the International Business Leaders' Advisory Council for the Mayor of Shanghai (IBLAC), president of the Flanders-China Chamber of Commerce, member of the advisory board of the Conference Board China Centre for Economics and Business in Beijing, member of the Board of the Concours Reine Elisabeth and senior member of the Conference Board New York.

Alexandre Van Damme is on the boards of Anheuser-Busch InBev and InBev-Baillet Latour (not-for-profit organisation). He is also a member of the INSEAD International Council and the Solvay Business School Consultative Council. Their appointments will broaden the skills of the Board. Following approval at the general assembly, the new Board will have eight independent members; Armand De Decker, Bert De Graeve, Peter Fellner, Jean-Pierre Kinet, Thomas Leysen, Tom McKillop, Gerhard Mayr, and Norman Ornstein.

The remaining members include Karel Boone, chairman, Evelyn du Monceau, vice chair, Roch Doliveux, executive director, Arnoud de Pret, Bridget van Rijckevorsel, Alexandre Van Damme and Gaëtan van de Werve. 

29th March 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics